Rebecca Armbruster, DO, MS, FACOI: Chief Medical Officer | Jeanes Hospital
Rebecca Armbruster, DO, MS, FACOI: Chief Medical Officer | Jeanes Hospital
Anjali Vaidya, MD, co-director of the Pulmonary Hypertension Program at Temple University Hospital, discussed findings related to sotatercept with MedPage Today. The addition of sotatercept to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients showed promise in delaying serious outcomes. These findings emerged from the ZENITH trial, presented at the American College of Cardiology annual meeting and published in the New England Journal of Medicine.
Alerts Sign-up